Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer
Krishan R. Jethwa(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), M. Petersen(Mayo Clinic in Arizona), Phanindra Antharam(Mayo Clinic in Arizona), Terence T. Sio(The University of Texas MD Anderson Cancer Center), Trey C. Mullikin(Cancer Institute (WIA)), William S. Harmsen(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Shilpa Sannapaneni(Texas Health Dallas), Kenneth W. Merrell(Mayo Clinic), Amit Mahipal(Dana-Farber Cancer Institute), Þorvarður R. Hálfdánarson(Mayo Clinic), Brady Laughlin(WinnMed)
Cited by 18
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530